LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers hope ...

When Spark Therapeutics announced an $850,000 price tag last week for its new gene therapy Luxturna, which treats a rare form of blindness, some critics held it up as the latest example of an ...

Please provide your email address to receive an email when new articles are posted on . Luxturna maintained long-term improvements in ambulatory vision, light sensitivity and visual field in patients ...

A new gene therapy to treat progressive blindness will cost $850,000, the company that makes it said Wednesday. Subscribe to read this story ad-free Get unlimited access to ad-free articles and ...

Please provide your email address to receive an email when new articles are posted on . Interim safety data from a post-authorization study of Luxturna in patients with genetic retinal diseases were ...

WASHINGTON — U.S. health officials on Tuesday approved the nation's first gene therapy for an inherited disease, a treatment that improves the sight of patients with a rare form of blindness. It marks ...

Luxturna is the first directly administered gene therapy approved in the U.S. that targets a disease caused by mutations in a specific gene. Luxturna (voretigene neparvovec-rzyl; Spark Therapeutics) ...

Biomedicine just took a giant step forward in the U.S. This week, the U.S. Food and Drug Administration approved Luxturna, a form of gene therapy that seeks to treat retinal dystrophy, a rare eye ...